Deficiency of interleukin-36 receptor antagonist
DITRA is caused by loss of function mutations in the IL36RN gene (codes for the IL-36 receptor antagonist), which leads to loss of inhibition of the IL-36 receptor resulting in overexpression of NFkB, MAPK, and proinflammatory interleukins, such as interleukin-8 (IL-8), which recruits neutrophils to the skin. Often, a homozygous mutation is present, indicating an autosomal recessive inheritance pattern; however, compound heterozygous mutations have also been documented.
While the age of onset is often in infancy or childhood, onset in adolescence and adulthood has been reported. DITRA is marked by repeated, sudden-onset flares of pustular psoriasis that occur at variable intervals. Viral or bacterial infections, retinoid withdrawal, menstruation, and pregnancy have been documented as triggers for these flares.
DITRA can be a life-threatening illness and has a reported 4%-7% mortality rate without treatment.
M04.8 – Other autoinflammatory syndromes
784339002 – Deficiency of interleukin 36 receptor antagonist
Differential Diagnosis & Pitfalls
- Deficiency of interleukin-1 receptor antagonist (DIRA)
- Pustular psoriasis
- Acute generalized exanthematous pustulosis
- Eosinophilic pustular folliculitis of infancy
- NOCARH syndrome (neonatal-onset cytopenia, autoinflammation, rash, hemophagocytic lymphohistiocytosis)
- PRAID syndrome (POMP-related autoinflammation and immune dysregulation)
- CARD14-associated papulosquamous eruption (CAPE)
- Cutaneous candidiasis
- Tinea corporis
- Netherton syndrome
- Acrodermatitis enteropathica (hereditary and acquired)
- IgA pemphigus